The demonstration that PTH signalling continues after PTH/PTH1R internalisation [23] is driving research to develop a PTHrP derivative with extended activity which will enhance the benefits of intermittent treatment with abaloparatide, a human parathyroid hormone-related peptide analogue, on bone mineral density in osteoporosis [9,23,112]. This evidence concerns the gene PTH and osteoporosis.